吗啡硫酸盐甲醇溶液,64-31-3，生产厂家，价格-洛克化工网移动版

返回



基本信息

物化性质

安全信息

毒理性

MSDS

下游产品

吗啡硫酸盐甲醇溶液

中文名称：: 吗啡硫酸盐甲醇溶液

中文别名：: 吗啡硫酸盐甲醇

英文名称：: MORPHINE SULFATE NARCOTIC ANALGESIC

英文别名：: morphine sulfate;
Oramorph;
NIH 0001;
Kadian;
Oblioser;
morphin sulfate;
Avinza;
Morphelan;
Morphine sulfate;
Capros;
morphine sulphate;
Skenan;
Kapanol;
Relipain

CAS No.：: 64-31-3

分子式：: C18H25NO8S

分子量：: 415.458

精确分子量：: 383.10400

PSA：: 135.91000

InChI：: The Key: OOZBZVAQKFGLOL-VYKNHSEDSA-N3

风险术语：: 11-23/24/25-39/23/24/25

SDS：: 查看

吗啡硫酸盐甲醇溶液毒理性

CHEMICAL IDENTIFICATION

RTECS NUMBER :: QC8750000

CHEMICAL NAME :: Morphinan-3,6-alpha-diol, 7,8-didehydro-4, 5-alpha-epoxy-17-methyl-, sulfate

CAS REGISTRY NUMBER :: 64-31-3

LAST UPDATED :: 199712

DATA ITEMS CITED :: 56

MOLECULAR FORMULA :: C34-H38-N2-O6.H2-O4-S

MOLECULAR WEIGHT :: 668.82

WISWESSER LINE NOTATION :: T B6566 B6/CO 4ABBC R BX HO PN DU GHT&&TTJ FQ JQ P& 2WSQQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 8 mg/kg

TOXIC EFFECTS :: Behavioral - analgesia

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 12 mg/kg/4W-I

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 461 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 235 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 108 mg/kg

TOXIC EFFECTS :: Endocrine - other changes

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 70 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 78 mg/kg

TOXIC EFFECTS :: Behavioral - changes in motor activity (specific assay) Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 600 mg/kg

TOXIC EFFECTS :: Behavioral - analgesia

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 275 mg/kg

TOXIC EFFECTS :: Behavioral - analgesia

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 180 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - changes in motor activity (specific assay)

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 156 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Behavioral - rigidity (including catalepsy)

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 334 mg/kg

TOXIC EFFECTS :: Behavioral - changes in motor activity (specific assay) Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intracerebral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 5100 ug/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 316 mg/kg

TOXIC EFFECTS :: Behavioral - analgesia Behavioral - sleep

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 1 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 391 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 400 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - hamster

DOSE/DURATION :: 1250 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Bird - pigeon

DOSE/DURATION :: 321 mg/kg

TOXIC EFFECTS :: Behavioral - ataxia Behavioral - convulsions or effect on seizure threshold

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Bird - chicken

DOSE/DURATION :: 125 mg/kg

TOXIC EFFECTS :: Behavioral - ataxia Behavioral - convulsions or effect on seizure threshold Behavioral - somnolence (general depressed activity)

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Bird - duck

DOSE/DURATION :: 213 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Amphibian - frog

DOSE/DURATION :: 677 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Parenteral

SPECIES OBSERVED :: Amphibian - frog

DOSE/DURATION :: 678 mg/kg

TOXIC EFFECTS :: Behavioral - ataxia Behavioral - changes in psychophysiological tests

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3100 mg/kg/18W-C

TOXIC EFFECTS :: Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 60 gm/kg/14W-C

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - fibrosis, focal (pneumoconiosis) Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3150 mg/kg/9W-I

TOXIC EFFECTS :: Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - changes in prostate weight

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 430 mg/kg/14W-I

TOXIC EFFECTS :: Blood - hemorrhage Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 22 mg/kg

SEX/DURATION :: male 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 140 mg/kg

SEX/DURATION :: female 9-22 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - behavioral

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 50 mg/kg

SEX/DURATION :: female 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - ovaries, fallopian tubes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 592 mg/kg

SEX/DURATION :: female 5 day(s) pre-mating female 1-22 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 1420 mg/kg

SEX/DURATION :: female 5 day(s) pre-mating - 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 1420 mg/kg

SEX/DURATION :: female 5 day(s) pre-mating - 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 50 mg/kg

SEX/DURATION :: female 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - other measures of fertility

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 1400 mg/kg

SEX/DURATION :: male 28 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 141 mg/kg

SEX/DURATION :: female 7-9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 187 mg/kg

SEX/DURATION :: female 17-20 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Effects on Newborn - other postnatal measures or effects

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 187 mg/kg

SEX/DURATION :: female 17-20 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - behavioral

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 450 mg/kg

SEX/DURATION :: female 7 day(s) pre-mating female 3-16 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 20 mg/kg

SEX/DURATION :: female 21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2800 mg/kg

SEX/DURATION :: female 8-21 day(s) after conception lactating female 14 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - behavioral

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 10 mg/kg

SEX/DURATION :: male 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 400 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 100 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 400 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 500 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 840 mg/kg

SEX/DURATION :: female 5 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 200 mg/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 1900 mg/kg

SEX/DURATION :: female 11 day(s) pre-mating female 1-29 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Newborn - physical

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 82 mg/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 206 mg/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

TYPE OF TEST :: Micronucleus test

TYPE OF TEST :: Cytogenetic analysis

MUTATION DATA

TEST SYSTEM :: Rodent - mouse

DOSE/DURATION :: 10 mg/kg

REFERENCE :: TCMUD8 Teratogenesis, Carcinogenesis, and Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1980- Volume(issue)/page/year: 3,19,1983 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - A1172 No. of Facilities: 33 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 198 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - A1172 No. of Facilities: 201 (estimated) No. of Industries: 2 No. of Occupations: 10 No. of Employees: 17783 (estimated) No. of Female Employees: 15877 (estimated)

吗啡硫酸盐甲醇溶液 MSDS

模块 1. 化学品
  1.1 产品标识符
    : 吗啡硫酸盐溶液
    产品名称
  1.2 鉴别的其他方法
    无数据资料
  1.3 有关的确定了的物质或混合物的用途和建议不适合的用途
    仅用于研发。不作为药品、家庭或其它用途。

模块 2. 危险性概述
  2.1 GHS-分类
    易燃液体 (类别 2)
    急性毒性, 经口 (类别 3)
    急性毒性, 吸入 (类别 3)
    急性毒性, 经皮 (类别 3)
    特异性靶器官系统毒性（一次接触） (类别 1)
  2.2 GHS 标记要素，包括预防性的陈述
    象形图
    警示词        危险
    危险申明
    H225        高度易燃液体和蒸气
    H301        吞咽会中毒
    H311        皮肤接触会中毒
    H331        吸入会中毒。
    H370        对器官造成损害。
    警告申明
    预防措施
    P210        远离热源、火花、明火和热表面。- 禁止吸烟。
    P233        保持容器密闭。
    P240        容器和接收设备接地。
    P241        使用防爆的电气/ 通风/ 照明设备。
    P242        只能使用不产生火花的工具。
    P243        采取措施，防止静电放电。
    P260        不要吸入粉尘/ 烟/ 气体/ 烟雾/ 蒸汽/ 喷雾。
    P264        操作后彻底清洁皮肤。
    P270        使用本产品时不要进食、饮水或吸烟。
    P271        只能在室外或通风良好之处使用。
    P280        戴防护手套/穿防护服/戴护目镜/戴面罩.
    事故响应
    P301 + P310        如果吞下去了: 立即呼救解毒中心或医生。
    P303 + P361 + P353        如果皮肤(或头发)接触：立即除去/脱掉所有沾污的衣物，用水清洗皮肤/淋
    浴。
    P304 + P340        如吸入: 将患者移到新鲜空气处休息，并保持呼吸舒畅的姿势。
    P307 + P311        如接触到：呼叫解毒中心或医生。
    P322        具体处置（见本标签上提供的急救指导）。
    P330        漱口。
    P361        立即除去/脱掉所有沾污的衣物。
    P363        沾污的衣服清洗后方可再用。
    P370 + P378        火灾时：用干的砂子，干的化学品或耐醇性的泡沫来灭火。
    安全储存
    P403 + P233        存放于通风良的地方。保持容器密闭。
    P403 + P235        保持低温，存放于通风良好处。
    P405        存放处须加锁。
    废弃处置
    P501        将内容物/ 容器处理到得到批准的废物处理厂。
  2.3 其它危害物 - 无

模块 3. 成分/组成信息
  3.2 混合物
    : C34H38N2O6 · H2SO4
    分子式
    : 668.75 g/mol
    分子量
    组分        分类        浓度或浓度范围
    Methanol
    化学文摘登记号(CA 67-56-1        Flam. Liq. 2; Acute Tox. 3;        50 - 100 %
    S No.)        200-659-6        STOT SE 1; H225, H301,
    EC-编号        603-001-00-X        H311, H331, H370
    索引编号        01-2119433307-44-XXXX
    注册号
    Morphine sulphate
    化学文摘登记号(CA        64-31-3        Acute Tox. 4; Repr. 2; H302,        0.1 - 0.25 %
    S No.)        200-582-8        H361
    EC-编号
    如需在本章节中提及的H类告知和R类描述的全部文字说明,请见第16章节.

模块 4. 急救措施
  4.1 必要的急救措施描述
    一般的建议
    请教医生。向到现场的医生出示此安全技术说明书。
    吸入
    如果吸入,请将患者移到新鲜空气处。如呼吸停止,进行人工呼吸。请教医生。
    皮肤接触
    用肥皂和大量的水冲洗。立即将患者送往医院。请教医生。
    眼睛接触
    用大量水彻底冲洗至少15分钟并请教医生。
    食入
    禁止催吐。切勿给失去知觉者通过口喂任何东西。用水漱口。请教医生。
  4.2 主要症状和影响，急性和迟发效应
    如吞服甲醇可能致命或致盲。, 不能制成无毒性的。, 摄入的影响可包括：, 恶心, 头晕, 消化系统失调, 虚弱,
    混乱, 嗜睡, 失去知觉, 据我们所知，此化学，物理和毒性性质尚未经完整的研究。
  4.3 及时的医疗处理和所需的特殊处理的说明和指示
    无数据资料

模块 5. 消防措施
  5.1 灭火介质
    灭火方法及灭火剂
    用水雾,抗乙醇泡沫,干粉或二氧化碳灭火。
  5.2 源于此物质或混合物的特别的危害
    碳氧化物
  5.3 给消防员的建议
    如必要的话,戴自给式呼吸器去救火。
  5.4 进一步信息
    用水喷雾冷却未打开的容器。

模块 6. 泄露应急处理
  6.1 作业人员防护措施、防护装备和应急处置程序
    戴呼吸罩。避免吸入蒸气、烟雾或气体。保证充分的通风。移去所有火源。人员疏散到安全区域。
    谨防蒸气积累达到可爆炸的浓度。蒸气能在低洼处积聚。
  6.2 环境保护措施
    如能确保安全，可采取措施防止进一步的泄漏或溢出。不要让产品进入下水道。
  6.3 泄漏化学品的收容、清除方法及所使用的处置材料
    围堵溢出，用防电真空清洁器或湿刷子将溢出物收集起来，并放置到容器中去,根据当地规定处理(见第13部
    分)。
  6.4 参考其他部分
    丢弃处理请参阅第13节。

模块 7. 操作处置与储存
  7.1 安全操作的注意事项
    避免接触皮肤和眼睛。避免吸入蒸气和烟雾。
    切勿靠近火源。－严禁烟火。采取措施防止静电积聚。
  7.2 安全储存的条件,包括任何不兼容性
    贮存在阴凉处。使容器保持密闭，储存在干燥通风处。
    打开了的容器必须仔细重新封口并保持竖放位置以防止泄漏。
    建议的贮存温度： -20 °C
  7.3 特定用途
    无数据资料

模块 8. 接触控制和个体防护
  8.1 容许浓度
    最高容许浓度
    组分        化学文摘登        值        容许浓度        基准
    记号(CAS
    No.)
    Methanol        67-56-1        PC-        25 mg/m3        工作场所有害因素职业接触限值 -
    TWA        化学有害因素
    备注        皮
    PC-        50 mg/m3        工作场所有害因素职业接触限值 -
    STEL        化学有害因素
    皮
  8.2 暴露控制
    适当的技术控制
    避免与皮肤、眼睛和衣服接触。休息前和操作本品后立即洗手。
    个体防护设备
    眼/面保护
    面罩與安全眼鏡请使用经官方标准如NIOSH (美国) 或 EN 166(欧盟) 检测与批准的设备防护眼部。
    皮肤保护
    戴手套取手套在使用前必须受检查。
    请使用合适的方法脱除手套(不要接触手套外部表面),避免任何皮肤部位接触此产品.
    使用后请将被污染过的手套根据相关法律法规和有效的实验室规章程序谨慎处理. 请清洗并吹干双手
    所选择的保护手套必须符合EU的89/686/EEC规定和从它衍生出来的EN 376标准。
    身体保护
    全套防化学试剂工作服, 阻燃防静电防护服,
    防护设备的类型必须根据特定工作场所中的危险物的浓度和数量来选择。
    呼吸系统防护
    如危险性评测显示需要使用空气净化的防毒面具，请使用全面罩式多功能防毒面具（US）或ABEK型
    （EN
    14387）防毒面具筒作为工程控制的候补。如果防毒面具是保护的唯一方式，则使用全面罩式送风防
    毒面具。呼吸器使用经过测试并通过政府标准如NIOSH（US）或CEN（EU）的呼吸器和零件。

模块 9. 理化特性
  9.1 基本的理化特性的信息
    a) 外观与性状
    形状: 液体
    b) 气味
    无数据资料
    c) 气味阈值
    无数据资料
    d) pH值
    无数据资料
    e) 熔点/凝固点
    无数据资料
    f) 沸点、初沸点和沸程
    无数据资料
    g) 闪点
    11 °C - 闭杯
    h) 蒸发速率
    无数据资料
    i) 易燃性(固体,气体)
    无数据资料
    j) 高的/低的燃烧性或爆炸性限度无数据资料
    k) 蒸气压
    无数据资料
    l) 蒸汽密度
    无数据资料
    m) 密度/相对密度
    无数据资料
    n) 水溶性
    无数据资料
    o) n-辛醇/水分配系数
    无数据资料
    p) 自燃温度
    无数据资料
    q) 分解温度
    无数据资料
    r) 粘度
    无数据资料

模块 10. 稳定性和反应活性
  10.1 反应性
    无数据资料
  10.2 稳定性
    无数据资料
  10.3 危险反应
    无数据资料
  10.4 应避免的条件
    热,火焰和火花。极端温度和直接日晒。
  10.5 不相容的物质
    酸, 氧化剂, 碱金属, 强氧化剂, 酰基氯, 酸酐, 还原剂
  10.6 危险的分解产物
    其它分解产物 - 无数据资料

模块 11. 毒理学资料
  11.1 毒理学影响的信息
    急性毒性
    无数据资料
    皮肤刺激或腐蚀
    无数据资料
    眼睛刺激或腐蚀
    无数据资料
    呼吸道或皮肤过敏
    无数据资料
    生殖细胞致突变性
    无数据资料
    致癌性
    IARC:
    此产品中没有大于或等于 0。1%含量的组分被 IARC鉴别为可能的或肯定的人类致癌物。
    生殖毒性
    无数据资料
    特异性靶器官系统毒性（一次接触）
    无数据资料
    特异性靶器官系统毒性（反复接触）
    无数据资料
    吸入危险
    无数据资料
    潜在的健康影响
    吸入        吸入会中毒。引起呼吸道刺激。
    摄入        误吞会中毒。
    皮肤        如果被皮肤吸收会有毒性造成皮肤刺激。
    眼睛        造成严重眼刺激。
    接触后的征兆和症状
    如吞服甲醇可能致命或致盲。, 不能制成无毒性的。, 摄入的影响可包括：, 恶心, 头晕, 消化系统失调, 虚弱,
    混乱, 嗜睡, 失去知觉, 据我们所知，此化学，物理和毒性性质尚未经完整的研究。
    附加说明
    化学物质毒性作用登记: 无数据资料

模块 12. 生态学资料
  12.1 生态毒性
    无数据资料
  12.2 持久性和降解性
    无数据资料
  12.3 潜在的生物累积性
    无数据资料
  12.4 土壤中的迁移性
    无数据资料
  12.5 PBT 和 vPvB的结果评价
    无数据资料
  12.6 其它不良影响
    无数据资料

模块 13. 废弃处置
  13.1 废物处理方法
    产品
    在装备有加力燃烧室和洗刷设备的化学焚烧炉内燃烧处理,特别在点燃的时候要注意,因为此物质是高度易燃
    性物质将剩余的和不可回收的溶液交给有许可证的公司处理。
    受污染的容器和包装
    按未用产品处置。

模块 14. 运输信息
  14.1 联合国危险货物编号
    欧洲陆运危规: 1230        国际海运危规: 1230        国际空运危规: 1230
  14.2 联合国运输名称
    欧洲陆运危规: METHANOL, 溶液
    国际海运危规: METHANOL, 溶液
    国际空运危规: Methanol, 溶液
  14.3 运输危险类别
    欧洲陆运危规: 3 (6.1)        国际海运危规: 3 (6.1)        国际空运危规: 3 (6.1)
  14.4 包裹组
    欧洲陆运危规: II        国际海运危规: II        国际空运危规: II
  14.5 环境危险
    欧洲陆运危规: 否        国际海运危规        国际空运危规: 否
    海洋污染物（是/否）: 否
  14.6 对使用者的特别提醒
    无数据资料

模块 15 - 法规信息
N/A

模块16 - 其他信息
N/A

吗啡硫酸盐甲醇溶液

吗啡硫酸盐甲醇溶液物化性质

吗啡硫酸盐甲醇溶液安全信息

吗啡硫酸盐甲醇溶液毒理性

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

MUTATION DATA

吗啡硫酸盐甲醇溶液 MSDS

吗啡硫酸盐甲醇溶液下游产品

推荐供应商

吗啡硫酸盐甲醇溶液

吗啡硫酸盐甲醇溶液 物化性质

吗啡硫酸盐甲醇溶液 安全信息

吗啡硫酸盐甲醇溶液 毒理性

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

MUTATION DATA

吗啡硫酸盐甲醇溶液 MSDS

吗啡硫酸盐甲醇溶液 下游产品

推荐供应商

吗啡硫酸盐甲醇溶液物化性质

吗啡硫酸盐甲醇溶液安全信息

吗啡硫酸盐甲醇溶液毒理性

吗啡硫酸盐甲醇溶液下游产品